Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab plus carboplatin and paclitaxel for locally advanced esophageal squamous cell carcinoma
ChiCTR2200062251Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jul 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, carboplatin and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: Safety and Pathological complete response rate. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
camrelizumabcarboplatinpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200062251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062251.